Patients with adenoid cystic carcinoma and MYB overexpression are included in the ongoing MYPHISMO trial with novel vaccination approach, used synergistically with programmed cell death protein 1 (PD-1) inhibitors [57]. Here, PDCD1 is linked to adenoid cystic carcinoma.